A Phase 3 interventional study of Saline and Exendin-9,39 in Healthy, sponsored by Adrian Vella. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Adrian Vella · Phase 3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study to find out how genetic variations in GLP1R alter insulin secretion, in the fasting state and when blood sugars levels are elevated.
Adrian Vella is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Saline will be infused during the study
Other: Saline
Exendin-9,39 will be infused during the study
Biological: Exendin-9,39
Liraglutide will be infused during the study
Biological: Liraglutide
Saline will serve as the control
Exendin-9,39 will block the GLP-1 receptor
Liraglutide will serve as the GLP-1 receptor agonist/stimulator
Average Insulin Secretion in Response to Hyperglycemia
Insulin secretion was estimated from C-peptide concentrations using the deconvolution method which incorporates c-peptide kinetics, and the subject's age, body surface area, body mass index, and diabetes status. A hyperglycemic clamp will be used which allows the glucose to be maintained at 160mg/dL (9mmol/L). C-peptide concentrations were drawn every 10 minutes from -30 minutes to 180 minutes, and the insulin secretion at 180 minutes was reported.
Time frame: insulin secretion rate at the end of the hyperglycemic clamp i.e.: 180 minutes
Change in Glucagon Secretion Rate Measured by Immunoassay
The Glucagon secretion rate during fasting (0 minutes) and at the end of the hyperglycemic clamp (180 minutes).
Time frame: 0 Minutes, 180 Minutes
| Milestone | Saline Exendin Victoza | Saline Victoza Exendin | Exendin Saline Victoza | Exendin Victoza Saline | Victoza Saline Exendin | Victoza Exendin Saline |
|---|---|---|---|---|---|---|
| Started | 7 | 2 | 6 | 1 | 1 | 3 |
| Completed | 6 | 1 | 6 | 1 | 0 | 2 |
| Not completed | 1 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Loss of iv | 0 | 0 | 0 | 0 | 1 | 0 |
Insulin secretion was estimated from C-peptide concentrations using the deconvolution method which incorporates c-peptide kinetics, and the subject's age, body surface area, body mass index, and diabetes status. A hyperglycemic clamp will be used which allows the glucose to be maintained at 160mg/dL (9mmol/L). C-peptide concentrations were drawn every 10 minutes from -30 minutes to 180 minutes, and the insulin secretion at 180 minutes was reported.
| μIU/mL | Saline | Exendin-9, 39 | Liraglutide |
|---|---|---|---|
| AG Genotype | 17 ± 2 | 13 ± 1 | 154 ± 12 |
| AA Genotype | 33 ± 3 | 58 ± 23 | 542 ± 143 |
| GG Genotype | 23 ± 3 | 16 ± 2 | 184 ± 17 |
The Glucagon secretion rate during fasting (0 minutes) and at the end of the hyperglycemic clamp (180 minutes).
| pmol/min | Saline | Exendin-9,39 | Liraglutide |
|---|---|---|---|
| AG Genotype 0 Minutes | 20.6 ± 5.5 | 22.8 ± 4.6 | 22.1 ± 3.4 |
| AA Genotype 0 Minutes | 36.4 ± 7.9 | 57.7 ± 15.3 | 46.0 ± 6.4 |
| GG Genotype 0 Minutes | 18.7 ± 1.3 | 19.3 ± 2.5 | 17.2 ± 1.9 |
| AG Genotype 180 Minutes | 5.8 ± 0.1 | 6.4 ± 0.6 | 6.3 ± 0.1 |
| AA Genotype 180 Minutes | 6.6 ± 0.1 | 6.5 ± 0.1 | 6.3 ± 0.1 |
| GG Genotype 180 Minutes | 6.1 ± 0.1 | 6.0 ± 0.1 | 6.0 ± 0.2 |
Collected over Adverse events were collected from the time of informed consent through study completion, approximately 16 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saline | 0/17 (0%) | 0/17 (0%) | 4/17 (23.5%) |
| Exendin-9,39 | 0/17 (0%) | 0/17 (0%) | 3/17 (17.6%) |
| Liraglutide | 0/17 (0%) | 1/17 (5.9%) | 7/17 (41.2%) |
| Event | Saline | Exendin-9,39 | Liraglutide |
|---|---|---|---|
| Nausea/Emesis/Sweating DiaphoresisGastrointestinal disorders | 0/17 | 0/17 | 1/17 |
| Event | Saline | Exendin-9,39 | Liraglutide |
|---|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 0/17 | 1/17 | 3/17 |
| Nausea/VomitingGastrointestinal disorders | 2/17 | 1/17 | 2/17 |
| Flushed/Hot/DiaphoreticSkin and subcutaneous tissue disorders | 1/17 | 1/17 | 2/17 |
| HeadacheNervous system disorders | 2/17 | 0/17 | 1/17 |
| Asymptomatic hypoglycemiaMetabolism and nutrition disorders | 0/17 | 0/17 | 1/17 |
| Lightheaded/Shaky/Pale/SweatyNervous system disorders | 1/17 | 0/17 | 0/17 |
| HypotensionVascular disorders | 0/17 | 1/17 | 0/17 |
| Age, Continuous(years) | Saline, Exednin-9, 39 and Liraglutide |
|---|---|
| Mean | 46.8 ± 3.9 |
| Sex: Female, Male(Participants) | Saline, Exednin-9, 39 and Liraglutide |
|---|---|
| Female | 14 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Saline, Exednin-9, 39 and Liraglutide |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Saline, Exednin-9, 39 and Liraglutide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Saline, Exednin-9, 39 and Liraglutide |
|---|---|
| United States | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Sep 2025, 35 months.
Results were first posted in Oct 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Avexitide · Liraglutide
Adrian Vella